Retatrutide

Retatrutide (LY3437943) is Eli Lilly's next-generation obesity peptide, a once-weekly injectable that activates three metabolic receptors at once: GIP, GLP-1, and glucagon. In the Phase 2 obesity study reported in NEJM in 2023, participants lost roughly 24% of body weight at 48 weeks on the top dose [1], one of the largest sustained weight-loss signals seen with any single molecule tested to that point. The Phase 3 TRIUMPH-1 topline reported by Lilly on May 21, 2026 confirmed and extended that signal: 28.3% mean weight loss at 12 mg over 80 weeks in adults with obesity or overweight without diabetes, with 45.3% of top-dose participants reaching at least 30% weight loss, and up to 30.3% at 104 weeks in a high-BMI extension subgroup [2][12]. Lilly guided to a U.S. BLA submission in Q1 2027 [12]. The broader Phase 3 program includes TRANSCEND-T2D-2 (n=1,250) [3], the 10,000-patient TRIUMPH-Outcomes cardiovascular and kidney outcomes trial [4], and a MASH (metabolic dysfunction-associated steatohepatitis, a form of severe fatty liver disease) platform study, SYNERGY-Outcomes (n=4,500) [5]. With TRIUMPH-1 primary endpoint met, retatrutide is on track to become the successor asset to tirzepatide (Zepbound/Mounjaro) inside Lilly's own portfolio, with an efficacy ceiling that leapfrogs every currently approved GLP-1 competitor, including semaglutide. Lilly's total revenue was $65.2B in FY2025, up 45% year over year, driven primarily by Mounjaro and Zepbound volume, per the FY2025 10-K filed February 2026 [6].

First-in-class triple agonist. Retatrutide is a novel investigational peptide (RxNorm CUI 2722410, FDA UNII NOP2Y096GV). TRIUMPH-1 obesity (NCT05929066, n=2,335) reported positive topline on May 21, 2026: 28.3% mean weight loss at 12 mg over 80 weeks, dose-dependent response (25.9% at 9 mg, 19.0% at 4 mg, 2.2% placebo), and 45.3% of 12 mg participants achieving at least 30% body weight reduction [2][12]. Lilly guided to a U.S. BLA submission in Q1 2027 [12]. The remaining Phase 3 program is unusually broad. TRANSCEND-T2D-2 (NCT06260722) is active-not-recruiting with 1,250 T2D patients and HbA1c change as primary [3]. TRIUMPH-Outcomes (NCT06383390) is the 10,000-patient cardiovascular and kidney outcomes trial, powered on time to first MACE plus renal composite [4]. SYNERGY-Outcomes (NCT07165028), a MASH master protocol with 4,500 patients, is actively recruiting with time to major adverse liver outcomes as the primary [5]. A separate obesity-plus-chronic low back pain study (NCT07035093, n=586) is active-not-recruiting with a pain intensity primary endpoint [7]. No public FDA breakthrough or fast track designation has been disclosed for retatrutide as of publication. The long-tail catalyst is TRIUMPH-Outcomes, which will run into the late 2020s given the required MACE event accrual. Lilly's FY2025 10-K discusses retatrutide as a key late-stage pipeline asset for the incretin franchise [6].

Retatrutide hits three receptors that gut and pancreas hormones normally use to coordinate metabolism. GLP-1 (glucagon-like peptide-1) is the hormone released after meals that tells the pancreas to make insulin and tells the brain the person is full. That mechanism drives Ozempic and Wegovy. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also boosts insulin, but the more interesting piece is that GIP signaling in fat tissue and the brain appears to increase energy expenditure and improve how the body handles fat storage. Tirzepatide (GIP plus GLP-1) validated stacking the two. Glucagon is the counterintuitive third target. Glucagon normally raises blood sugar by telling the liver to release glucose, so putting it in a diabetes/obesity drug sounds backward. The rationale: glucagon also increases basal metabolic rate, drives fat oxidation in the liver, and burns calories. The bet is that the GLP-1 arm cancels glucagon's glucose-raising effect, while glucagon's calorie-burning kick stacks on top of GIP/GLP-1 appetite suppression. Phase 2 supported the thesis. Weight loss exceeded any single-molecule benchmark [1], glycemic control held, and cardiovascular biomarker changes reported by Ruotolo et al. in Diabetes Obes Metab 2026 pointed in the right direction [8]. A systematic review of retatrutide RCTs found consistent improvements in blood pressure and lipids [9]. Phase 3 TRIUMPH-1 confirmed the thesis at scale [12].

The Phase 3 program is built to answer both the efficacy and the payer questions. TRIUMPH-1 (NCT05929066) was the standard obesity registration study, 2,335 patients, percent change in body weight as the primary endpoint. Topline reported in May 2026 hit primary and dose-response, with 12 mg reaching 28.3% mean weight loss over 80 weeks [2][12]. TRIUMPH-Outcomes (NCT06383390) is the important one for regulators and reimbursement: 10,000 adults with obesity, diabetes not required, primary endpoint is time to first occurrence of a composite that includes cardiovascular death, non-fatal MI, non-fatal stroke, and renal outcomes [4]. This mirrors the SELECT playbook Novo Nordisk used to unlock broad Medicare and commercial coverage for semaglutide. TRANSCEND-T2D-2 (NCT06260722) is the head-to-head fight with semaglutide, 1,250 T2D patients on metformin with or without SGLT2, primary is HbA1c change [3]. If retatrutide wins here, Lilly gets a superiority label against Ozempic in T2D, which changes prescribing at scale. SYNERGY-Outcomes (NCT07165028) is a MASH platform trial with 4,500 patients and hard hepatic outcomes as primary [5]. Execution risk has largely shifted from patient enrollment to regulatory submission (TRIUMPH-1 BLA in Q1 2027) and event accrual on the outcomes trials. A network meta-analysis published in BMJ 2026 already ranked retatrutide at the top of the obesity pharmacology comparison [10], and the TRIUMPH-1 readout raised the bar further.

Our model estimates a 34% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 66%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results, a randomized design, and a comparator/control arm. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk in the obesity indication is now largely retired. Phase 2 was decisive [1] and TRIUMPH-1 confirmed and extended the signal [12]. The real questions are safety and commercial. Safety-wise, glucagon activation raises hepatic glucose output, resting heart rate, and potentially blood pressure. Phase 2 and Phase 3 both showed dose-dependent heart rate increases consistent with the class, and Ruotolo et al. reported favorable cardiovascular biomarker trajectories overall [8], but hard MACE will not read out until TRIUMPH-Outcomes accrues events years from now [4]. Prior glucagon-containing programs (AstraZeneca's cotadutide, Boehringer's survodutide dual) hit dose-limiting nausea, muted differentiation, or attenuated cardiovascular signals. Retatrutide has not shown those failure modes at the doses tested, but longer exposure in the outcomes trials matters. Execution risk: Lilly is running multiple Phase 3 trials in parallel on this molecule while already facing tirzepatide manufacturing constraints. Lilly's FY2025 10-K commentary highlights ongoing multi-billion-dollar peptide manufacturing capacity expansion, but retatrutide-specific capacity has not been separately quantified in public guidance [6]. Commercial risk is the most interesting layer. CagriSema's REDEFINE-4 head-to-head failed non-inferiority against tirzepatide (20.2% vs 23.6% at 84 weeks) in February 2026 [14], leaving retatrutide as the differentiated efficacy leader but competing directly with Lilly's own Mounjaro/Zepbound franchise. If the safety and tolerability profile is not clearly better than tirzepatide, or the incremental weight loss beyond real-world dose maximums is smaller than the trial ceiling suggests, the launch faces internal cannibalization and payer pushback on incremental price. The path to franchise growth rather than substitution runs through the MASH and cardiovascular outcomes reads, not the obesity registration alone.

Signal, not noise. TRIUMPH-1 answered the obesity efficacy question in May 2026 at 28.3% mean weight loss on 12 mg over 80 weeks and up to 30.3% at 104 weeks in a high-BMI extension [12]. The remaining questions are whether retatrutide beats tirzepatide on axes payers actually pay for, and whether Lilly can make enough of it. Four data points still to watch. First, TRANSCEND-T2D-2 head-to-head against semaglutide on HbA1c and secondary weight endpoints [3]. A superiority signal reshapes Ozempic prescribing at the primary care level. Second, TRIUMPH-Outcomes interim safety, particularly resting heart rate, blood pressure, lipids, and any component imbalance in MACE [4]. Third, SYNERGY-Outcomes MASH histology and liver enzyme trajectories, because MASH is the next large obesity-adjacent category and a glucagon-containing molecule has a mechanistic reason to outperform GLP-1 monotherapy on hepatic fat clearance [5]. Fourth, Lilly's Q1 2027 U.S. BLA filing for the obesity indication [12]. Competitive frame: Novo Nordisk (CagriSema, NDA filed December 2025, U.S. decision expected Q4 2026, but REDEFINE-4 failed non-inferiority against tirzepatide [14]), Amgen (MariTide, monthly GLP-1/GIP-antagonist, Phase 3 completion targeted 2027), Boehringer/Zealand (survodutide GLP-1/glucagon dual, Phase 3 SYNCHRONIZE ongoing, ~19% Phase 2 weight loss), and Viking (VK2735 oral and injectable, entering Phase 3) [13][14]. Retatrutide is the efficacy benchmark those programs are trying to match or differentiate from. Patent horizon: tirzepatide's primary U.S. composition-of-matter patent expires November 23, 2036, with method-of-use extensions running into 2041 and realistic biosimilar entry 2037-2040 [15]. Retatrutide's composition-of-matter patent horizon extends further into the late 2030s, giving Lilly a rolling incretin exclusivity window that can absorb the tirzepatide cliff if the succession thesis executes. Lilly's $65.2B in FY2025 revenue is levered heavily to incretin performance [6], and retatrutide is the asset that decides whether the next leg is growth or defense.